Shares of Vertex Pharmaceuticals Incorporated (VRTX) are down more than 8% Friday morning.
Thursday the company said it will not advance VX-864, the company's investigational drug in Phase 2 study for the treatment of people with alpha-1 antitrypsin deficiency (AATD), into late-stage development.
"Although results provide proof-of-mechanism, the magnitude of treatment effect observed in this study is unlikely to translate into substantial clinical benefit," Vertex said.
VRTX touched a 52-week low of $193 this morning. The stock is currently trading at $198.91
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.